top of page
Buscar

Avanzanite licenses Zemcelpro stem cell therapy commercialisation rights across 32 European countries

Foto do escritor: nuaxia
nuaxia
9 de nov.
2 min de leitura

Avanzanite has secured exclusive European commercialisation rights to Cordex Biologics' conditionally authorised cord-blood stem cell therapy Zemcelpro, covering 32 countries under new licensing and supply agreements.


Avanzanite Bioscience and Cordex Biologics announced exclusive licensing and supply agreements on 9 November 2026 covering Zemcelpro (dorocubicel) across the European Economic Area, United Kingdom and Switzerland, with Avanzanite assuming commercial responsibilities and the existing EU marketing authorisation following regulatory transfer.


The allogeneic cord-blood-derived therapy received European Commission conditional marketing authorisation on 25 August 2025 for specified adults with haematological malignancies requiring transplantation when suitable donor cells are unavailable, while Cordex retains manufacturing and global development responsibilities and the new agreements include undisclosed development fees, commercial milestones and royalties.

Field

Content

Article Type

Deals

Licensee

Avanzanite Bioscience

Licensor

Cordex Biologics

Deal Type

Exclusive commercialisation licensing and supply agreements

Announcement Date

9 November 2026

Agreement Status

Announced

Licensed Product

Zemcelpro

Active Ingredient

Dorocubicel

Technology Designation

UM171 cell therapy

Therapy Type

Allogeneic cord-blood-derived stem cell therapy

Therapeutic Area

Haematology and oncology

Target Patient Population

Eligible adults with haematological malignancies requiring stem cell transplantation when suitable donor cells are unavailable

Treatment Context

Haematopoietic stem cell transplantation

Licensed Territory

32 European countries

Territory Coverage

European Economic Area, United Kingdom and Switzerland

Commercial Rights

Exclusive commercialisation rights within the licensed territory

Licensee Responsibilities

Commercial operations and regional market access

Marketing Authorisation Transfer

Avanzanite to assume the existing EU marketing authorisation following regulatory transfer

Licensor Responsibilities

Manufacturing and global development

Supply Arrangement

Commercial supply agreement included

European Regulatory Authority

European Commission

Existing EU Approval Type

Conditional marketing authorisation

Existing EU Authorisation Date

25 August 2025

UK Regulatory Status

Authorisation remains prospective as described in the supplied announcement

Swiss Regulatory Status

Authorisation remains prospective as described in the supplied announcement

Development Programme

Planned Phase III study

Licensee Development Role

Support for the planned Phase III study

Financial Structure

Development fees, commercial milestones and royalties

Upfront Payment

Not disclosed

Milestone Amounts

Not disclosed

Royalty Rates

Not disclosed

Total Deal Value

Not disclosed

New European Commission Approval

No; the EU conditional authorisation predates the licensing announcement

What Happened

Avanzanite obtained exclusive commercialisation rights to Zemcelpro across 32 European countries through licensing and supply agreements with Cordex.

Why It Matters

The transaction establishes a dedicated European commercialisation arrangement for a specialised stem cell therapy addressing transplantation needs in haematological malignancies.

Strategic Significance

Separates regional commercial execution from Cordex's retained manufacturing and global development responsibilities.

Regulatory Clarification

Commercial rights covering the United Kingdom and Switzerland do not establish that Zemcelpro is authorised in those jurisdictions.

Key Takeaway

Avanzanite will lead European commercialisation of Zemcelpro under undisclosed financial terms, subject to applicable regulatory and market-access requirements.

What to Watch

Marketing authorisation transfer, country-level reimbursement, UK and Swiss regulatory progress, commercial launches and Phase III development.

Primary Source

Avanzanite and Cordex licensing announcement

Primary Source URL

https://www.prnewswire.com/news-releases/zemcelpro-um171-cell-therapy-licensing-and-supply-agreements-announced-for-europe-302933369.html

Relevant Date

9 November 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

Comentários

Avaliado com 0 de 5 estrelas.
Ainda sem avaliações

Adicione uma avaliação
bottom of page